Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > What we know so far…

<< Previous

Bullboard Posts

Next >>

Comment by Lesalpes29on Jan 22, 2023 9:14pm

174 Views

Post# 35238985

RE:RE:RE:RE:What we know so far…

Noteable wrote: Right .. Phase 3 when aacquired.

https://www.gilead.com/news-and-press/press-room/press-releases/2020/9/gilead-sciences-to-acquire-immunomedics

Noteable you can shoot every buyout numbers from the past but in the end it could be 2B. And it's probably enough for all the members of the BOD and for most of the longs here! Have a good week,

<< Previous

Bullboard Posts

Next >>

Hempalta acquires controlling interest in Hemp Carbon Standard